0 0 Gilbert's Pharma Limited 10497204 true 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is that of a retail pharmacy up unitl 30 September 2022, when the company sold its trade and assets. Since the disposal of the trade and assets, the company has continued to receive and pay any remaining balances. Digita Accounts Production Advanced 6.30.9574.0 true false 10497204 2025-01-01 2025-12-31 10497204 2025-12-31 10497204 core:RetainedEarningsAccumulatedLosses 2025-12-31 10497204 core:ShareCapital 2025-12-31 10497204 core:CurrentFinancialInstruments 2025-12-31 10497204 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 10497204 bus:SmallEntities 2025-01-01 2025-12-31 10497204 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 10497204 bus:FilletedAccounts 2025-01-01 2025-12-31 10497204 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 10497204 bus:RegisteredOffice 2025-01-01 2025-12-31 10497204 bus:Director1 2025-01-01 2025-12-31 10497204 bus:EntityNoLongerTradingButTradedInPast 2025-01-01 2025-12-31 10497204 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 10497204 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-01-01 2025-12-31 10497204 countries:EnglandWales 2025-01-01 2025-12-31 10497204 2024-01-01 2024-12-31 10497204 core:CurrentFinancialInstruments 2024-12-31 10497204 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 xbrli:pure iso4217:GBP

Registration number: 10497204

Prepared for the registrar
Gilbert's Pharma Limited
Annual Report and Unaudited Financial Statements
for the Year Ended 31 December 2025

Gilbert's Pharma Limited

Contents

Balance Sheet | 1
Notes to the Unaudited Financial Statements | 2 to 4

Gilbert's Pharma Limited

(Registration number: 10497204)
Balance Sheet as at 31 December 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Investments | 4 | 7,500 | 7,500
Creditors: Amounts falling due within one year | 6 | (358,600) | (358,600)
Net liabilities |  | (351,100) | (351,100)
Capital and reserves |  |  |
Called up share capital |  | 100 | 100
Profit and loss account |  | (351,200) | (351,200)
Total equity |  | (351,100) | (351,100)

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 19 August 2026

Mr D Gilbert
Director

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

| 1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
C/O Hazlewoods LLP
Staverton Court
Staverton
Cheltenham
Gloucestershire
GL51 0UX
United Kingdom

| 2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

The company ceased to trade on 30 September 2022 when the trade and assets were sold and there are no plans to recommence trading in the future. Accordingly, the directors do not consider it appropriate to prepare the financial statements on a going concern basis. This includes, where applicable, writing the company's assets down to their net realisable value and making provisions against contracts that have become onerous at the reporting date. No material adjustments arose as a result of ceasing to apply the going concern basis.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.
A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

| 3 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2024 - 0).

| 4 | Investments

| 2025 £ | 2024 £
Other investments | 7,500 | 7,500

| 5 | Debtors

| 2025 £ | 2024 £
| - | -

| 6 | Creditors

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Loans and borrowings | 7 | 358,600 | 358,600

Gilbert's Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

| 2025 £ | 2024 £

| 7 | Loans and borrowings

Current loans and borrowings

| 2025 £ | 2024 £
Other borrowings | 358,600 | 358,600

| 8 | Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company.
As at the balance sheet date, the company owed the director £358,600 (2024 - £358,600). There are no fixed repayment terms and no interest is charged on the loan.